Rumored Buzz on ABBV-744 as a potential therapeutic option for aggressive cancers
These side effects ended up notably milder when compared to an inhibitor of each bromodomains. A detailed molecular Investigation also disclosed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor- "Our study uncovered the vital part on the KLF16/MYC regulatory axis in modulating tumo